June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Comparison of macular atrophy progression in nAMD eyes and non-nAMD fellow eyes
Author Affiliations & Notes
  • Miltiadis K Tsilimbaris
    Ophthalmological Clinic, University Hospital of Heraklion, Panepistemio Kretes Iatrike Schole, Heraklion, Crete, Greece
  • Stella Blazaki
    Ophthalmological Clinic, University Hospital of Heraklion, Panepistemio Kretes Iatrike Schole, Heraklion, Crete, Greece
  • Emmanouil Blavakis
    Ophthalmological Clinic, University Hospital of Heraklion, Panepistemio Kretes Iatrike Schole, Heraklion, Crete, Greece
  • Georgios Bontzos
    Ophthalmology, Korgialenio-Benakio General Hospital, Athens, Greece
  • Georgios Smoustopoulos
    Ophthalmology, Korgialenio-Benakio General Hospital, Athens, Greece
  • Eleni Dimitriou
    2nd Department of Ophthalmology, Attikon Hospital, Ethniko kai Kapodistriako Panepistemio Athenon Iatrike Schole, Athens, Attica, Greece
  • Eirini Chatziralli
    2nd Department of Ophthalmology, Attikon Hospital, Ethniko kai Kapodistriako Panepistemio Athenon Iatrike Schole, Athens, Attica, Greece
  • Anastasios Stavrakakis
    Ophthalmological Clinic, University Hospital of Heraklion, Panepistemio Kretes Iatrike Schole, Heraklion, Crete, Greece
  • Matina Kabanarou
    Ophthalmology, Korgialenio-Benakio General Hospital, Athens, Greece
  • Tina Xirou
    Ophthalmology, Korgialenio-Benakio General Hospital, Athens, Greece
  • Gregory Chlouverakis
    Department of Biostatistics, Panepistemio Kretes Iatrike Schole, Heraklion, Crete, Greece
  • Footnotes
    Commercial Relationships   Miltiadis Tsilimbaris None; Stella Blazaki None; Emmanouil Blavakis None; Georgios Bontzos None; Georgios Smoustopoulos None; Eleni Dimitriou None; Eirini Chatziralli None; Anastasios Stavrakakis None; Matina Kabanarou None; Tina Xirou None; Gregory Chlouverakis None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 350 – F0181. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Miltiadis K Tsilimbaris, Stella Blazaki, Emmanouil Blavakis, Georgios Bontzos, Georgios Smoustopoulos, Eleni Dimitriou, Eirini Chatziralli, Anastasios Stavrakakis, Matina Kabanarou, Tina Xirou, Gregory Chlouverakis; Comparison of macular atrophy progression in nAMD eyes and non-nAMD fellow eyes. Invest. Ophthalmol. Vis. Sci. 2022;63(7):350 – F0181.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Τo evaluate the evolution of MA in patients with neovascular AMD (nAMD) treated with anti-vascular endothelial growth factor (anti-VEGF) agents, compared with their fellow eyes exhibiting dry AMD.

Methods : This retrospective study included 124 patients from three centers with neovascular AMD treated with anti-VEGF intravitreal injections in one eye and dry AMD in the fellow eye. We analyzed data from two groups of patients: 91 patients without MA at baseline in order to study time to first MA development in treated and fellow eyes, and 47 patients with a total of 4 years of follow-up in order to study time course and growth rate of MA in treated and fellow eyes. MA was evaluated using NIR images, while all available OCT images were used to confirm that the atrophic area fulfilled the criteria proposed by the Classification of Atrophy Meetings (CAM) group.

Results : MA first detection in treated eyes (TE) increased in significant levels from year 2 to year 6 in comparison with fellow eyes (FE). Presence of MA during the 4-year of follow up was recorded in 50% of TE and in 18% of FE. Repeated measures ANOVA revealed significant time, eye and time eye interaction effects. MA in treated eyes exhibited a steady significant increase up to year 6, whereas in the FE the significant increase is halted at year 4. The annual increase in the TE was 0.275 mm/y [0.10 mm/y for year 1, 0.23 mm/y for year 2, 0.37 mm/y for year 3, and 0.49 mm/y for year 4]. The respective annual increase for the FE was 0.110 mm/y; [0.09 mm/y for year 1, 0.14 mm/y for year 2, 0.11 mm/y for year 3 and 0.10 mm/y for year 4].

Conclusions : In this study we documented a significant difference in MA incidence and progression in eyes with nAMD treated with anti-VEGF agents compared to fellow eyes exhibiting dry AMD. Treated nAMD eyes tend to develop more often MA; moreover, MA progresses in a faster rate in these eyes compared to fellow dry AMD eyes.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×